Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

A flexible implantable contraceptive disc device is disclosed which can be inserted inside the female body, such as inside the uterus, is disclosed. The disc device can be bent and inserted into a laparoscopy tube, which allows it to be delivered to an appropriate location inside a female subject. The disc device has three layers, a central core silicon reservoir containing an active ingredient, such as a contraceptive progesterone, which is sandwiched and encased by upper and lower porous silicon casings. The casings are porous to the contraceptive, allowing controlled release over a prolonged period of time. The lower casing has a series of micro-hooks around a circumference, allowing the disc device to be attached to a desired tissue by rotating the disc device such that the hooks engage with the desired tissue. Such a device is easier to insert, and to remove, than a rod-like rigid plastic T-shape IUDs which are considerably larger, also and more expensive to manufacture.

Apparatus for delivering a therapeutic agent to a uterine cavity including an elongated member having a fluid channel for passage of the therapeutic agent into the uterine cavity, a dispensing member extending distally of the elongated member and having at least one perforation for passage of the therapeutic agent into the uterine cavity into contact with the endometrium. An infusion line is in communication with the fluid channel for passage of a fluid into the uterine cavity to assess leakage to determine integrity of the uterine cavity prior to passage of the therapeutic agent into the uterine cavity.

The present invention provides an automatic drug delivery device. The automatic drug delivery device includes an enclosure and a first piston disposed in the enclosure. The first piston partitions the enclosure to a first drug delivery chamber and a first expansion chamber. A first through hole and a second through hole are formed in the wall of the enclosure, the first through-hole communicates with the first drug delivery chamber, and the second through-hole communicates with the first expansion chamber. A first targeted dissolution membrane covers the first through hole and the second through hole, and dissolves at a first targeted region. A drug is filled in the first drug delivery chamber, and an expandable material is included in the first expansion chamber. The expandable material in the first expansion chamber can expand after absorbing liquid.

The present disclosure provides a gastroretentive drug delivery device having an expandable structure. The drug delivery device includes: a capsule body; an arm moving part movable within the capsule body; an elastic body positioned between one end of the capsule body and the arm moving part and acting to move the arm moving part toward the other end of the capsule body; an arm support part movable within the capsule body; a capsule cap configured to engage the other end of the capsule body; a rail formed within the capsule body; and an arm configured to be unfolded by longitudinal movement of the arm moving part and move along the rail. A disintegrable immediate-release formulation is positioned between the arm moving part and the arm support part. A disintegrable sustained-release formulation is positioned between the arm support part and the capsule cap.

An apparatus includes a chamber container and a tray. The chamber container has a first portion and a second portion removably coupled to the first portion. The first and second portions collectively define an inner volume. The tray is configured to be removably disposed within the inner volume of the chamber container. The tray includes a first portion and a second portion coupled to the first portion via a hinge. The first portion includes a first retention surface. The second portion includes a second retention surface. The tray is configured to receive a biodiffusion chamber between the first portion and the second portion such that the first retention surface and the second retention surface engage a portion of the biodiffusion chamber to (1) place the biodiffusion chamber in a predetermined orientation and (2) maintain the biodiffusion chamber in a substantially fixed position relative to the tray.

A method is used to insert an implant within a lateral wall of a nose of a patient. The method includes forming an initial incision with a surface of the lateral wall of the nose. A stylet is advanced within the lateral wall of the nose, thereby creating a pocket within the lateral wall of the nose. The stylet is further advanced until an expanding body of the stylet is at least partially housed within the pocket of the lateral wall. The expanding body of the stylet is enlarged to thereby enlarge the pocket within the lateral wall. The implant is placed within the enlarged pocket of the lateral wall.

A pharmaceutical product including a housing that defines a cavity, wherein the cavity stores a pharmaceutical material, and wherein the housing comprises a material configured to dissolve based on contact with a fluid, an ingestible device to encode information in a current signature, wherein the ingestible device is positioned within the housing, and a protective material that encompasses the ingestible device. The ingestible device may be attached to a flexible component, wherein the flexible component is configured to releasably secure the ingestible device within the housing.

An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.

In another example, a bioresorbable implant for use in a nasal region includes one or more bioresorbable polymers, and a pharmaceutical composition coupled to the one or more bioresorbable polymers. A release rate of the pharmaceutical composition is related to a degradation rate of the one or more bioresorbable polymers.